Floatz logo

Bemarituzumab

Locally Advanced or Metastatic Renal Cell Carcinoma

Fujian Cancer Hospitalmonoclonal_antibodyPhase 2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

297 Active assets in the Locally Advanced or Metastatic Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Sorafenib
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 4BBB
gw786034
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 4BBB
Belzutifan
Vall d'Hebron Institute of Oncology
Phase 3BBB
Alpha-Interferon
National Cancer Institute (NCI)
Phase 3BBB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB

View all 50 →

Same molecule, other indications

Bemarituzumab is also rated in:

endometrial carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
bladder transitional cell carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
cervical cancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →